Acutaas Chemicals
Market cap ₹32,677 Cr
- P/E
- 74.72
- Day range
- ₹3,934.20 – ₹4,017.60
- 52-week range
- ₹1,570.00 – ₹4,130.00
- Volume
- 2.44 L
- Open
- ₹3,935.00
- Prev close
- ₹3,942.90
Latest results · Q2 FY27(consolidated)Revenue ₹437 Cr+42.7%Profit ₹123 Cr+71.4%Margin 28.2%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
ACUTAAS in NSE indices and F&O
Research profile
Composite 64 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.3%
- Graham no.
- ₹520.31
- vs Graham
- -87.0%
- ROE ÷ P/B
- 1.4%
- 12-1 mom.
- +81.7%
- Return / vol
- 2.78
- Magic Formula
- #309
- Piotroski
- 4/6
- FCF yield
- -0.1%
Appears in 19 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Acutaas ChemicalsACUTAAS | ₹32,677 Cr | 74.72 | 17.79 | 24.0% | 32.0% | 40.0% | 0.01 | +42.8% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 6h agoHeadlines about Acutaas Chemicals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 74.4
- EPS (TTM)
- ₹47.06
- Price / Book
- 17.58
- ROE (FY26)
- 24.0%
- ROCE (latest year)
- 32%
- Dividend yield
- 0.06%
Moving averages (NSE)
- 20-day
- ₹3,759.26
- Price above
- 50-day
- ₹3,447.19
- Price above
- 200-day
- ₹2,951.97
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the split of 25 Apr 2025: earlier bars are per pre-split share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 | 437 |
| Expenses | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 | 261 |
| Operating Profit | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 | 176 |
| OPM % | 16% | 19% | 17% | 20% | 25% | 28% | 25% | 31% | 38% | 42% | 34% | 40% |
| Other Income | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 | 5 |
| Interest | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 10 | 13 |
| Profit before tax | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 | 167 |
| Tax % | 25% | 31% | 26% | 25% | 28% | 24% | 24% | 25% | 27% | 27% | 28% | 26% |
| Net Profit | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 | 123 |
| EPS in Rs | ₹2.27 | ₹3.41 | ₹1.71 | ₹4.56 | ₹5.49 | ₹7.63 | ₹5.41 | ₹8.82 | ₹13.19 | ₹16.09 | ₹9.07 | ₹15.29 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-30 days since Mar 2021
+26 days since Mar 2021
-73 days since Mar 2021
+69 days since Mar 2021
+65 days since Mar 2021
Strengths, risks & growth
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals. [1]
Strengths
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 45.8% CAGR over last 5 years
Risks
- Stock is trading at 17.6 times its book value
- Promoter holding has decreased over last 3 years: -6.27%
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +32%
- 3 Years
- +30%
- TTM
- +45%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +46%
- 3 Years
- +62%
- TTM
- +96%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- +53%
- 3 Years
- +95%
- 1 Year
- +132%
Return on Equity
- 10 Years
- +20%
- 5 Years
- +18%
- 3 Years
- +18%
- Last Year
- +24%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 32.66% | 32.66% | 32.66% | 32.66% | 0.00 pp |
| FII | 16.67% | 19.48% | 21.61% | 22.61% | +1.00 pp |
| DII | 21.70% | 19.60% | 19.55% | 19.40% | -0.15 pp |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.00 pp |
| Public | 28.96% | 28.24% | 26.16% | 25.31% | -0.85 pp |
Filed with NSE for Sept 2026: promoters 32.66%, public 67.34%
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 45.4%
- Downside volatility
- 42.4%
- Worst 5% of days
- 4.1%
- Average of that tail
- 5.7%
- Max drawdown (1Y)
- 17.5%
- Below its peak
- 1.2%
Against the market
- Beta vs Nifty 50
- 0.74
- Correlation
- 0.22
- Relative strength (3M)
- +20.9%
- ATR (14)
- 4.1%
Return
- Return 1M
- +24.5%
- Return 3M
- +24.8%
- Return 6M
- +42.6%
- Return 1Y
- +126.2%
- vs 200-day average
- +35.2%
Momentum
- RSI (14)
- 65.1
- MACD histogram
- 5.19
- Stochastic %K
- 69.6
- ADX (14)
- 29.3
- +DI / −DI
- 26.2 / 13.4
- Money flow index
- 72.6
Participation
- Delivery (20d avg)
- 44.7%
- vs its 60-day baseline
- -3.2 pts
- Volume vs 20-day
- -0.6σ
- Close vs day's VWAP
- +0.0%
- 52-week position
- 98 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- -₹36 Cr
- FCF yield
- -0.1%
- Cash conversion
- 0.82
- Accruals ratio
- 0.032
- Net debt
- -₹274 Cr
- Net debt / equity
- -0.15
- EV / sales
- 20.35
- Capex intensity
- 24.5%
- Revenue CAGR
- 26.1%
- Profit CAGR
- 56.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
Hemant Mahendabhai Patel Designated Person · Pledge Creation | Pledge | 1,000 | ₹32.7 L | 2 Oct 2026 |
Vijay Gosar Employees/Designated Employees · Market Sale | Sell | 500 | ₹10.7 L | 10 Mar 2026 |
MEHUL MANSUKHBHAI KOLADIA Employees/Designated Employees · Market Sale | Sell | 20,000 | ₹4.2 Cr | 20 Feb 2026 |
Bhavesh Mansukhbhai Kotadiya Employees/Designated Employees · Market Purchase | Buy | 2,100 | ₹35.1 L | 30 Dec 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹2.50
Dividend - Rs 2.50 Per Share
17 Sept 2026ex-date - dividend₹1.50
Dividend - Rs 1.50 Per Share
18 Sept 2025ex-date - splitNot available — not reported in this filing
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share
25 Apr 2025ex-date - otherNot available — not reported in this filing
Annual General Meeting
13 Sept 2024ex-date - dividend₹3.00
Dividend - Rs 3 Per Share
13 Sept 2024ex-date - dividend₹3.00
Dividend - Rs 3 Per Share
18 Sept 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
18 Sept 2023ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
29 Jul 2022ex-date
Company announcements
Equirus Securities has organised an Earnings Conference Call on Tuesday, October 27, 2026 at 4.00 P.M. (IST) to discuss the financial results of the Company for the second quarter and half ....
Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve Unaudited standalone & consolidated ....
Completion of the Acquisition of the shares of the Step-down Subsidiary - Enchem Ami Organics Private Limited as per details attached.
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026 is attached.
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is enclosed.
Voting Results and Scrutinizers Report for the Annual General Meeting of the Company held on September 24, 2026 is attached.
Board of Directors have approved the acquisition of equity shares of step down subsidiary company as per details enclosed.
Disclosure of events of the 19th Annual General Meeting held on Thursday, September 24, 2026 is attached.
Intimation of Schedule of Investor Conference/Meet as per details attached.
Intimation of Closure of Trading Window is attached.
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is attached.
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 in respect of inauguration of Pilot Plant today at Unit-1 Sachin is enclosed.
Newspaper publication for dispatch of notice of 19th AGM along with Annual Report for the FY 2025-26 is enclosed.
Communication to shareholders issued in respect of deduction of TDS on Dividend , is herewith enclosed.
Intimation of Record date fixed for the purpose of Final Dividend for the FY 2025-26 is herewith enclosed.
Filed with BSE (scrip 543349); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Order
Exemption Order under Regulation 11 of SEBI (SAST) Regulations, 2011 in the matter of Acutaas Chemicals Limited - Patel and Vaghasia Family Trust
1 Oct 2025Read on SEBI - Order
Exemption Order under Regulation 11 of SEBI (SAST) Regulations, 2011 in the matter of Acutaas Chemicals Limited - Vaghasia Family Trust
1 Oct 2025Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Apr 2026Slides
- Feb 2026TranscriptSlidesRecording
- Oct 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 9 Dec 2025 from care
- Rating update · 26 Dec 2024 from care
- Rating update · 23 Nov 2023 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Acutaas Chemicals: common questions
Answered from the figures on this page.